|
R&D Leaders' Forum
Mikael Dolsten, MD, PhD, President, BioTherapeutics Research & Development, Pfizer Inc
Dr Jean-Pierre Lehner, Senior Vice President, Chief Medical Officer, Sanofi-Aventis
Dr John Fallon, Senior Vice President, Chief Physician Executive, Blue Cross Blue Shield of Massachusetts
Dr Eve E. Slater, former US Assistant Secretary for Health; Associate Clinical Professor, Columbia College of Physicians & Surgeons
Professor Jackie Hunter, Senior Vice President, Science Environment Development, GlaxoSmithKline
Steven D. Harr, MD, Managing Director & Analyst, Morgan Stanley
Dr Paul Trennery, Senior Vice President & Head of Externalisation, Preclinical Development, GlaxoSmithKline
John V. W. Reynders, PhD, Head of Integrative Neurosciences & Biomarkers & Head of the Informatics Center of Excellence, Johnson & Johnson
John Watson, President, Strategic Partnering & Integrated Drug Development, Covance Inc
Dr Richard J. Heaslip, Vice President, Project & Portfolio Management, Wyeth Research
Dr Ginger L. Gregory, Global Head of Human Resources, Novartis Institutes for BioMedical Research
Dr Tomasz Sablinski, Head of Development, Celtic Therapeutics Management LLLP
Dr Jeffrey Chodakewitz, Vice-President, Early Development Group Leader, Merck & Co
Dr Eric de La Fortelle, Global Head, External Research & Technologies, Roche
Dr Markus Thunecke, Senior Partner, Catenion GmbH
George M. Botsakos, Associate Partner - Strategy & Change, IBM Global Business Services
Dr J. Carmel Egan, Vice President, Project Management, Lilly Research Labs, Eli Lilly and Company
Jerald S. Schindler, DrPH, Vice President, Biostatistics & Research Decision Sciences - Late Development Statistics, Merck Research Laboratories
Valerie S. Kitchen, MD, FRCP, Vice President, Clinical Pharmacology Modelling & Simulation, Bristol-Myers Squibb
Donald R. Johns MD, Vice President, Deputy Global Head of Translational Medicine, Novartis Institutes for BioMedical Research
Frank Misselwitz, MD, PhD, Vice President & Head, Therapeutic Area Cardiovascular & Coagulation, Bayer HealthCare AG
Iain Cockburn, Professor of Finance & Economics, Boston University School of Management
Yannis Jemiai, PhD, Associate Director of Biostatistics, Cytel Inc
Aaron Schacht, Executive Director, Global External R&D, Eli Lilly and Company
Dr Greg Wiederrecht, Vice President & Head, External Scientific Affairs, Merck & Co
Dr Theodore Reiss, Corporate Vice President, Global Clinical Integrated Drug Development, Covance, Inc
William C. Bertrand, Executive Vice President, General Counsel & Corporate Compliance Officer, MedImmune, Inc
Dr Jeffrey Elton, Biotech Investor & Advisor & formerly Senior Vice President of Strategy & Chief Operating Officer, Novartis Institutes for BioMedical Research
Dr Michael Hale, Head of Global Medical Sciences Biostatistics Group, Amgen, Inc
Dr Peter Halle, Vice President, Early Stage Licensing, Merck Serono
Tom Swanekamp, Executive Director, Saftey & Risk Management, Pfizer Inc
Gary M. Phillips, MD, MBA, Global Head of Portfolio Management, Merck Serono International SA
Wayne A. Rosenkrans, Jr, PhD, Distinguished Fellow, MIT Center for Biomedical Innovation; Program in Ethics and Systems Medicine, Georgetown University; Chairman & President, Personalized Medicine Coalition; Vice President Strategic Consulting, Fuld and Co; Chief Applications Officer, SciTech Strategies
Rekha Hemrajani, Vice President, Business Development, Exelixis, Inc
Dr Richard Peck, Global Head of Clinical Pharmacology, Roche Products Ltd
Louise M. Perkins, PhD, Chief Scientific Officer, Multiple Myeloma Research Foundation
Dr Blaine McKee, Senior Vice President of Business Development, Oncology, Genzyme Corporation
Dr Jennifer Cermak, Director, Portfolio Management, Sirtris, a GSK Company
|
Oncology Leaders' Forum
Dr Lee M. Nadler, Dean of Clinical & Translational Research; Director, Harvard Catalyst; Virginia & D.K. Ludwig Professor of Medicine, Harvard Medical School, Senior Vice President, Experimental Medicine; Director, Center for Clinical & Translational Research; Pan Mass Challenge Senior Investigator, Dana-Farber Cancer Institute
Dr John Fallon, Senior Vice President, Chief Physician Executive, Blue Cross Blue Shield of Massachusetts
Steven D. Harr, MD, Managing Director & Analyst, Morgan Stanley
Dr Nancy Simonian, CMO, Millennium Pharmaceuticals, the Takeda Oncology Company
Jeremy N. Rich, MD, Chair, Department of Stem Cell Biology & Regenerative Medicine, Cleveland Clinic; Professor, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Co-Director, Center for Stem Cell & Regenerative Medicine, National Center for Regenerative Medicine
Roy Baynes, MD, PhD, Vice President, Global Clinical Development & Therapeutic Area Head Hematology/Oncology, Amgen, Inc
Stuart T. Henderson, Americas Life Sciences Pharma R&D Leader, IBM Global Business Services
Wayne A. Rosenkrans, Jr, PhD, Distinguished Fellow, MIT Center for Biomedical Innovation; Program in Ethics and Systems Medicine, Georgetown University; Chairman & President, Personalized Medicine Coalition; Vice President Strategic Consulting, Fuld and Co; Chief Applications Officer, SciTech Strategies
Michael O'Neal, MD, CMO, RadPharm, Inc
Darren J. Carroll, Vice President - New Ventures, Eli Lilly and Company
Leif W. Ellisen, MD, PhD, Associate Professor of Medicine, Harvard Medical School
Dr Cheryl Marks, Associate Director, Division of Cancer Biology, & Director, Mouse Models of Human Cancers Consortium (MMHCC), National Cancer Institute
Dr Jean-Pierre Bizzari, Senior Vice President, Clinical Oncology/Hematology, Celgene Corporation
Dr Clare Wareing, Founder & CEO, Nexus Oncology Ltd
Dr Geert Kolvenbag, Global Product Vice President, Oncology, AstraZeneca
Peter Duncan, Director - Business Development, Definiens
Dr Jeffrey Hanke, Vice President, Cancer Research, R&D Boston, AstraZeneca
Jian Wang, PhD, CEO, BioFortis
Dr William J. Slichenmyer, MD, ScM, CMO, AVEO Pharmaceuticals, Inc
Dr Peter Halle, Vice President, Early Stage Licensing, Merck Serono
Dr Blaine McKee, Senior Vice President of Business Development, Oncology, Genzyme Corporation
Dr Duncan McHale, Vice President of Translational Science, AstraZeneca
Christopher A. Slapak, MD, Distinguished Lilly Scholar (Executive Director), Eli Lilly and Company
Dr Robert E. Martell, Leader of the Program in Experimental Therapeutics, Tufts Medical Center Cancer Center
Dr Walter H. Koch, Vice President & Head of Research, Roche Molecular Systems, Inc
Dr Thomas C. Reynolds, Chief Medical Officer, Seattle Genetics
Dr Chris Holloway, Group Director of Regulatory Affairs & CSO, ERA Consulting Group
Dr Kevin Webster, Executive Director, Cancer BioScience, AstraZeneca
Dr Michael Shi, Senior Director, Biomarker Project Leader, Oncology Translational Medicine, Novartis Pharmaceuticals Corporation
Dr Francis Kalush, Diagnostics & Personalized Medicine Network Leader, Office Center Director, CDRH/FDA
Dr David Urdal, Chief Scientific Officer, Dendreon Corporation
David Apelian MD, PhD, MBA, Senior Vice President of R&D & Chief Medical Officer, GlobeImmune, Inc
Eric S. Perlman, MD, Vice President, Molecular Imaging, RadPharm, Inc
Louise M. Perkins, PhD, Chief Scientific Officer, Multiple Myeloma Research Foundation
Gary L. Yingling, Partner, K&L Gates LLP
Jared A. Gollob, MD, Senior Director, Clinical Research, Alnylam Pharmaceuticals
Dr Philip Breitfeld, Senior Medical Director, Global Clinical Development Unit - Oncology, EMD Serono, Inc
Dr Thomas W. Davis, Associate Director of Oncology, PTC Therapeutics
Dr Piyush Gupta, Researcher, Broad Institute
Dr Howard Higley, Director, Scientific Affairs, CCS Associates, Inc
Dr Laura K. Richman, Director, Pathology, Translational Sciences - Research, MedImmune,
|
